# Semaglutide Peptide

> Semaglutide is a long-acting GLP-1 receptor agonist that increases glucose-dependent insulin secretion, reduces appetite, and supports weight control.

Canonical: https://pepflow.app/peptides/semaglutide/

The GLP-1 Standard

A long-acting GLP-1 receptor agonist available as injection and tablets, used in modern obesity, diabetes, cardiovascular-risk, and kidney-outcome research and care.

Weight loss

Tier S

Evidence Strong

Safety Well-Studied

FDA status Approved

Last reviewed October 25, 2026 53 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is Semaglutide?

Semaglutide is a modified GLP-1 receptor agonist designed to last far longer than native GLP-1. The molecule activates the GLP-1 receptor, slows gastric emptying early in treatment, increases glucose-dependent insulin secretion, suppresses glucagon when glucose is elevated, and reduces appetite through central satiety pathways.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>)

For chronic weight management, the strongest evidence comes from large STEP trials of once-weekly subcutaneous semaglutide 2.4 mg, including weight-loss, maintenance, and two-year follow-up data.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/33567185/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/33755728/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/36216945/>)

Semaglutide also has large outcome trials in type 2 diabetes, cardiovascular-risk reduction, chronic kidney disease, and oral semaglutide cardiovascular outcomes. Those results make it very different from research-market peptides with only mechanism or animal data.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/27633186/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/37952131/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/38785209/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/40156843/>) For more context, read the [semaglutide reconstitution terminology guide](<https://pepflow.app/blog/how-to-reconstitute-semaglutide/>).

## What Semaglutide is investigated for

Semaglutide evidence is grouped by practical use case and injectable, oral, intranasal, sublingual, buccal, ophthalmic, transdermal, and inhaled route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Body-weight reduction and maintenance Injectable, Oral 95% Strong

Semaglutide is strongly supported for weight management when used as the labeled drug product in the right population and clinical setting.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/33567185/>)

#### Human evidence

STEP trials show large and sustained weight reductions with subcutaneous semaglutide 2.4 mg, including maintenance data and two-year follow-up.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/33567185/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/33755728/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/36216945/>)

#### Animal / mechanistic evidence

Mechanistic support comes from GLP-1 receptor effects on appetite, satiety, gastric emptying, and energy intake, but the human trial evidence is the main reason confidence is high.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>)

### ### Type 2 diabetes glycemic control Injectable, Oral 92% Strong

The diabetes use case is strong, but dose, route, and concomitant glucose-lowering therapy matter for hypoglycemia and tolerability.[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>)

#### Human evidence

Semaglutide injection and tablets have labeled diabetes indications, and STEP 2 shows weight and glycemic data in adults with type 2 diabetes and overweight or obesity.[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/33667417/>)

#### Animal / mechanistic evidence

The incretin mechanism is glucose-dependent, increasing insulin and reducing glucagon when glucose is elevated.[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>)

### ### Cardiovascular-risk reduction in selected populations Injectable, Oral 88% Strong

Cardiovascular benefit should be interpreted by trial population and label, not as a blanket claim for every semaglutide user.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/37952131/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/40156843/>)

#### Human evidence

SELECT, SUSTAIN-6, and SOUL support cardiovascular benefit in defined high-risk populations and product contexts.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/37952131/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/27633186/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/40156843/>)

#### Animal / mechanistic evidence

Mechanistic explanations likely include weight, glycemic, blood-pressure, lipid, inflammatory, and direct tissue effects, but human trials carry the claim.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/37952131/>)

### ### Kidney protection in type 2 diabetes with CKD Injectable 82% Strong

Confidence is high for the studied population, but it should not be generalized to kidney wellness claims outside that population.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/38785209/>)

#### Human evidence

FLOW reported kidney benefit in patients with type 2 diabetes and chronic kidney disease.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/38785209/>)

#### Animal / mechanistic evidence

The route-relevant mechanism is likely tied to metabolic, hemodynamic, and cardiometabolic effects rather than direct kidney-targeted peptide replacement.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/38785209/>)

### ### Neurodegenerative disease Oral 45% Preliminary

Large Alzheimer's trials did not confirm clinical benefit, so semaglutide remains an investigated GLP-1 therapy rather than an established neurodegenerative-disease treatment.[\[52\]](<https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916462>) [\[51\]](<https://pubmed.ncbi.nlm.nih.gov/39780249/>)

#### Human evidence

The EVOKE and EVOKE+ phase 3 trials tested oral semaglutide in early symptomatic Alzheimer's disease, but sponsor topline results reported no statistically significant reduction in disease progression versus placebo.[\[51\]](<https://pubmed.ncbi.nlm.nih.gov/39780249/>) [\[52\]](<https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916462>)

#### Animal / mechanistic evidence

GLP-1 receptor biology remains under study in neurodegenerative disease, including Parkinson's disease, but this does not establish semaglutide as a neuroprotective treatment.[\[53\]](<https://pubmed.ncbi.nlm.nih.gov/40067438/>)

## Evidence snapshot

### Overall confidence

Strong

92%

Semaglutide has one of the strongest human evidence profiles in this catalog: large randomized obesity trials, diabetes trials, FDA labeling, and hard-outcome studies all support specific clinical use cases.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/33567185/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/33667417/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/37952131/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/38785209/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

95%

### Human evidence

Strong

Large STEP, SUSTAIN, SELECT, FLOW, and SOUL datasets support weight, glycemic, cardiovascular, kidney, and oral semaglutide outcomes in the populations studied.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/33567185/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/27633186/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/37952131/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/38785209/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/40156843/>)

82%

### Animal / preclinical

Strong

Nonclinical and pharmacology support explains GLP-1 receptor activity, but human trials and approved labeling are the main reason confidence is high.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>)

90%

### Mechanism support

Strong

GLP-1 receptor activation links the observed outcomes to appetite regulation, gastric-emptying effects during initiation, glucose-dependent insulin secretion, and glucagon suppression when glucose is elevated.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>)

## Forms & administration

Semaglutide is supplied in approved injection pens and oral tablets with product-specific instructions. Nasal, sublingual, buccal, eye-drop, microneedle and inhaled formulations remain experimental, with evidence mainly from animals or laboratory delivery work. Their exposure, amounts and preparation cannot be equated with approved products.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>) [\[42\]](<https://pubmed.ncbi.nlm.nih.gov/42669320/>) [\[43\]](<https://pubmed.ncbi.nlm.nih.gov/41386332/>) [\[44\]](<https://pubmed.ncbi.nlm.nih.gov/37756378/>) [\[45\]](<https://pubmed.ncbi.nlm.nih.gov/40513668/>) [\[46\]](<https://pubmed.ncbi.nlm.nih.gov/34440130/>) [\[47\]](<https://pubmed.ncbi.nlm.nih.gov/41030572/>) [\[48\]](<https://pubmed.ncbi.nlm.nih.gov/38641020/>)

Injectable Oral Nasal spray Sublingual Buccal Ophthalmic Transdermal Inhaled

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Injectable semaglutide starts at 0.25 mg weekly. Maintenance doses are 0.5-2.4 mg, or 7.2 mg for the high-dose product. Oral products use 1.5-25 mg daily.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>)

### Frequency

Injectable products are taken once weekly. Oral tablets are taken once daily.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>)

### Timing Considerations

Use injections on the same day each week. Take tablets in the morning on an empty stomach and wait 30 minutes before eating or drinking.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>)

### Cycle Length

Treatment is ongoing. Standard dose increases take 3-4 months; the 7.2 mg dose requires at least 4 additional weeks.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/33755728/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/36216945/>)

[Full Semaglutide dosage guide](<https://pepflow.app/peptides/semaglutide/dosage/>)

## What to expect

### First weeks

Appetite is usually the first change people notice: smaller portions feel more manageable and fullness can arrive sooner.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/33567185/>)

### 3-6 months

Scale and waist changes usually become more visible, and appetite control can feel steadier as the routine settles.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/33567185/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/33755728/>)

### 1 year and beyond

Many responders maintain a lower weight with continued treatment, and cardiometabolic markers may remain improved while the medication effect is present.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/33755728/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/36216945/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/37952131/>)

### After stopping

Appetite can return toward baseline and weight regain is common after semaglutide is stopped; blood pressure, glucose, and lipid improvements may also soften.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/33755728/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/36216945/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/40186344/>)

## Safety profile

Semaglutide has a well-characterized prescription-drug safety profile. The main practical issues are GI intolerance, dehydration risk, gallbladder and pancreatitis warnings, diabetes-medication interactions, retinopathy caution in diabetes, pregnancy planning, and the boxed thyroid C-cell tumor warning.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>)

### Common side effects

- Nausea [\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>)
- Vomiting [\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>)
- Diarrhea [\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>)
- Constipation [\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>)

### Cautions

- Thyroid C-cell tumor warning[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>)
- Pancreatitis and gallbladder disease[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>)
- Insulin or sulfonylureas[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>)
- Pregnancy planning[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>)
- Compounded or unapproved GLP-1 products[\[4\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

## Who Semaglutide is not for

Route-specific avoid and medical-review notes:

- **MTC or MEN2 history**

  Semaglutide products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>)
- **Pregnancy planning**

  Labels instruct discontinuation before planned pregnancy because of semaglutide exposure and long washout considerations.[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Documented interactions

- **Insulin or sulfonylureas**

  Hypoglycemia risk can increase when semaglutide is combined with insulin secretagogues or insulin, so glucose-lowering therapy may need adjustment.[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>)
- **Levothyroxine or monitored oral drugs**

  Oral semaglutide delays gastric emptying and can change oral-drug exposure; the label specifically reports higher levothyroxine exposure and calls for closer monitoring of narrow-therapeutic-index or clinically monitored oral medicines.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>)

## Pairing notes

### Works well with

**Nutrition and activity intervention** Injectable, Oral

Nutrition and activity give semaglutide's appetite and weight-maintenance effects a structure to work inside: calorie targets, movement, and adherence routines support the medication effect rather than replacing it.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/33567185/>)

**Cagrilintide as an amylin partner** Injectable

Cagrilintide activates amylin pathways that increase satiety, while semaglutide activates GLP-1 pathways that reduce appetite and slow gastric emptying. Together they provide complementary appetite-control signals.[\[49\]](<https://pubmed.ncbi.nlm.nih.gov/40544433/>) [\[50\]](<https://pubmed.ncbi.nlm.nih.gov/40544432/>)

### Not recommended with

**Tirzepatide: overlapping GLP-1 effects** Injectable, Oral

Semaglutide and tirzepatide both activate GLP-1 pathways. Using them during overlapping courses duplicates effects on appetite, gastric emptying, and glucose control and requires clinician direction.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>)

**Retatrutide: overlapping GLP-1 effects** Injectable, Oral

Semaglutide and retatrutide both activate GLP-1 pathways. Overlapping them combines appetite, gastric-emptying, and glucose effects without an established combination regimen.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>)

## Regulatory status

### United States

United States: FDA-approved semaglutide drug products exist for specific indications and routes. Unapproved or compounded GLP-1 products are a separate regulatory and safety issue.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) [\[4\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Approved · Semaglutide injection appears in FDA-approved drug labeling for products such as Wegovy and Ozempic; indications and dosing depend on the specific product.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) | Not Listed · FDA warns that unapproved GLP-1 products used for weight loss can create dosing, ingredient, quality, and adverse-event risks. This is separate from FDA-approved semaglutide products.[\[4\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>) |
| Oral | Approved · Semaglutide tablets appear in FDA-approved labeling for oral products; tablet indications and administration requirements are not interchangeable with injectable products.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>) | Not Listed · FDA-approved tablets have specific formulation and administration requirements; compounded or research-market oral products should not be treated as interchangeable with labeled tablets.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>) [\[4\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>) |

### Injectable

FDA drug approval

Approved

Semaglutide injection appears in FDA-approved drug labeling for products such as Wegovy and Ozempic; indications and dosing depend on the specific product.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>)

503A compounding

Not Listed

FDA warns that unapproved GLP-1 products used for weight loss can create dosing, ingredient, quality, and adverse-event risks. This is separate from FDA-approved semaglutide products.[\[4\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

### Oral

FDA drug approval

Approved

Semaglutide tablets appear in FDA-approved labeling for oral products; tablet indications and administration requirements are not interchangeable with injectable products.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>)

503A compounding

Not Listed

FDA-approved tablets have specific formulation and administration requirements; compounded or research-market oral products should not be treated as interchangeable with labeled tablets.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>) [\[4\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

### International

International status depends on country, product name, indication, route, and local prescribing rules.

### Sports & competition

Semaglutide is not named as a prohibited substance in the reviewed 2026 WADA list, but athletes still need to follow medication, prescription, and event-specific rules.

## How it works

Semaglutide is a long-acting GLP-1 receptor agonist. The practical effect is appetite and calorie-intake reduction, plus glucose-dependent insulin release and lower glucagon when glucose is elevated, without making hypoglycemia irrelevant when insulin or sulfonylureas are used.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/33567185/>)

It also delays gastric emptying, which supports fullness but helps explain nausea, reflux-type symptoms, dehydration risk after vomiting or diarrhea, and oral-medicine timing concerns.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>)

Route and formulation matter: injectable and oral semaglutide have different exposure rules, and approved-product evidence does not make compounded, salt-form, or research-market products equivalent. Product and route drive the evidence.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>) [\[4\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

## Research gaps & open questions

What the current literature has not yet settled about Semaglutide:

01

Direct comparisons between approved tablets and injections need to show which effects, side effects, and dose conversions are formulation-specific; the products should not be substituted one-for-one.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>)

02

Long-term studies still need better answers on maintaining weight loss, stopping treatment, preserving muscle, supporting nutrition, and keeping treatment accessible.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/33755728/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/36216945/>)

## Common questions

### Is semaglutide a peptide?

Yes. It is a modified GLP-1 peptide analog, but it should be treated as a prescription drug product rather than a generic research peptide.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>)

### Are oral and injectable semaglutide interchangeable?

No. They are different product routes with different dose forms and administration rules, even though the active ingredient is semaglutide.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>)

### Does weight loss stay after stopping?

STEP 4 and related follow-up data show that continued treatment supports maintenance better than withdrawal; stopping can be followed by weight regain.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/33755728/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/36216945/>)

## Myths & misconceptions

### Myth

Any semaglutide product is basically the same as Wegovy or Ozempic.

### Reality

FDA-approved products have reviewed formulation, labeling, dose delivery, and quality controls. FDA has separately warned about unapproved GLP-1 products used for weight loss.[\[4\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>) [\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>)

### Myth

Semaglutide is only a weight-loss drug.

### Reality

Weight management is a major use case, but semaglutide also has diabetes, cardiovascular, oral-formulation, and kidney-outcome evidence in defined populations.[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/37952131/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/38785209/>)

## History & discovery

Semaglutide moved GLP-1 therapy from diabetes glucose control into obesity and broader cardiometabolic outcomes. Its history matters because the same incretin biology supported injectable, oral, and obesity-dose programs rather than one narrow obesity discovery.[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/33567185/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/27633186/>)

SUSTAIN-6 established cardiovascular-outcome context in type 2 diabetes, and STEP 1 made once-weekly semaglutide 2.4 mg a modern obesity-drug reference point.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/27633186/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/33567185/>)

SELECT, FLOW, SOUL, MASH research, and FDA GLP-1 safety materials widened the evidence story while keeping approved formulations separate from unapproved GLP-1 products and later liver-disease questions.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/37952131/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/38785209/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/40156843/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/40305708/>) [\[4\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

## Published research 53 citations

- [\[1\] **WEGOVY (semaglutide) injection and tablets prescribing information** U.S. Food and Drug Administration, 2026. regulatory.](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf>)
- [\[2\] **OZEMPIC (semaglutide) injection prescribing information** U.S. Food and Drug Administration, 2025. regulatory.](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf>)
- [\[3\] **RYBELSUS and OZEMPIC tablets prescribing information** U.S. Food and Drug Administration, 2026. regulatory.](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf>)
- [\[4\] **FDA's concerns with unapproved GLP-1 drugs used for weight loss** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)
- [\[5\] **FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from 503B bulks list** U.S. Food and Drug Administration. regulatory.](<https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list>)
- [\[6\] **Once-Weekly Semaglutide in Adults with Overweight or Obesity** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/33567185/>)
- [\[7\] **Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes** The Lancet. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/33667417/>)
- [\[8\] **Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance** JAMA. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/33755728/>)
- [\[9\] **Two-year effects of semaglutide in adults with overweight or obesity** Nature Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/36216945/>)
- [\[10\] **Semaglutide and cardiovascular outcomes in obesity without diabetes** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/37952131/>)
- [\[11\] **Semaglutide and cardiovascular outcomes in patients with type 2 diabetes** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/27633186/>)
- [\[12\] **Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/38785209/>)
- [\[13\] **Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40156843/>)
- [\[14\] **STEP 1: semaglutide 2.4 mg weight-management trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT03548935>)
- [\[15\] **Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology** Ophthalmology, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/42132708/>)
- [\[16\] **Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial** JAMA cardiology, 2026. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/41879791/>)
- [\[17\] **Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations** Journal of the Chinese Medical Association : JCMA, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/41857480/>)
- [\[18\] **Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial** JAMA internal medicine, 2026. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/41627802/>)
- [\[19\] **Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity** The New England journal of medicine, 2025. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40934115/>)
- [\[20\] **Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis** The New England journal of medicine, 2025. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40305708/>)
- [\[21\] **Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis** Obesity reviews : an official journal of the International Association for the Study of Obesity, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40186344/>)
- [\[22\] **Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial** Lancet (London, England), 2025. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40169145/>)
- [\[23\] **Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes** The New England journal of medicine, 2025. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40162642/>)
- [\[24\] **Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials** Diabetes care, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40156846/>)
- [\[25\] **Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis** Metabolism: clinical and experimental, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/39719170/>)
- [\[26\] **Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis** The New England journal of medicine, 2024. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/39476339/>)
- [\[27\] **Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial** Nature medicine, 2025. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/39455729/>)
- [\[28\] **Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials** Metabolism: clinical and experimental, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/39305981/>)
- [\[29\] **Evaluating the safety profile of semaglutide: an updated meta-analysis** Current medical research and opinion, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/39046272/>)
- [\[30\] **Clinical Pharmacokinetics of Semaglutide: A Systematic Review** Drug design, development and therapy, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38952487/>)
- [\[31\] **Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials** The American journal of cardiology, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38679221/>)
- [\[32\] **Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review** International journal of molecular sciences, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38673931/>)
- [\[33\] **Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials** Lancet (London, England), 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38582569/>)
- [\[34\] **Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis** BMJ (Clinical research ed.), 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38286487/>)
- [\[35\] **Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis** Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38029929/>)
- [\[36\] **Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial** Diabetes, obesity & metabolism, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38016699/>)
- [\[37\] **The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials** The American journal of clinical nutrition, 2023. review.](<https://pubmed.ncbi.nlm.nih.gov/37661106/>)
- [\[38\] **Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis** Journal of the ASEAN Federation of Endocrine Societies, 2022. review.](<https://pubmed.ncbi.nlm.nih.gov/36578889/>)
- [\[39\] **Semaglutide for the treatment of overweight and obesity: A review** Diabetes, obesity & metabolism, 2023. review.](<https://pubmed.ncbi.nlm.nih.gov/36254579/>)
- [\[40\] **Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis** Annals of internal medicine, 2020. review.](<https://pubmed.ncbi.nlm.nih.gov/32598218/>)
- [\[41\] **Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials** The lancet. Diabetes & endocrinology, 2019. review.](<https://pubmed.ncbi.nlm.nih.gov/31422062/>)
- [\[42\] **Intranasal delivery of Semaglutide using a thermoresponsive PNPHO nanocarrier: formulation development, characterization and biological evaluation.** International journal of pharmaceutics, 2026 Oct 05. animal.](<https://pubmed.ncbi.nlm.nih.gov/42669320/>)
- [\[43\] **Single-dose pharmacokinetics of sublingual semaglutide in rats.** European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2026 Feb 01. animal.](<https://pubmed.ncbi.nlm.nih.gov/41386332/>)
- [\[44\] **Boosting systemic absorption of peptides with a bioinspired buccal-stretching patch.** Science translational medicine, 2023 Sep 27. animal.](<https://pubmed.ncbi.nlm.nih.gov/37756378/>)
- [\[45\] **A biodegradable suction patch for sustainable transbuccal peptide delivery.** Journal of controlled release : official journal of the Controlled Release Society, 2025 Aug 10. animal.](<https://pubmed.ncbi.nlm.nih.gov/40513668/>)
- [\[46\] **Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes.** Biomedicines, 2021 Jul 31. animal.](<https://pubmed.ncbi.nlm.nih.gov/34440130/>)
- [\[47\] **Fabrication and Preclinical Evaluation of Hyaluronic Acid/Aminoclay Nanocomposite Microneedles for Noninvasive Delivery of Semaglutide in Anti-Obesity Therapy.** International journal of nanomedicine, 2025. animal.](<https://pubmed.ncbi.nlm.nih.gov/41030572/>)
- [\[48\] **Enhanced oral and pulmonary delivery of biomacromolecules via amplified transporter targeting.** Journal of controlled release : official journal of the Controlled Release Society, 2024 Jun. animal.](<https://pubmed.ncbi.nlm.nih.gov/38641020/>)
- [\[49\] **Coadministered cagrilintide and semaglutide in adults with overweight or obesity** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40544433/>)
- [\[50\] **Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40544432/>)
- [\[51\] **evoke and evoke+: design of two large-scale, double-blind, placebo-controlled phase 3 trials of semaglutide in early Alzheimer's disease** Alzheimer's Research & Therapy, 2025. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/39780249/>)
- [\[52\] **Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression** Novo Nordisk, 2025-11-24. human clinical.](<https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916462>)
- [\[53\] **Efficacy and safety of GLP-1 agonists in Parkinson's disease** Parkinsonism & Related Disorders, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40067438/>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Incretin/amylin analog

**Tier**

S

**Evidence**

92% Strong

**Safety**

Well-Studied

**FDA status**

Approved

**Injectable 503A**

Not Listed

**Citations**

[53 citations](<https://pepflow.app/peptides/semaglutide/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- Body-weight reduction and maintenance
- Type 2 diabetes glycemic control
- Cardiovascular-risk reduction in selected populations
- Kidney protection in type 2 diabetes with CKD
- Neurodegenerative disease

### Common side effects

- Nausea
- Vomiting
- Diarrhea

### Also known as

- Generic or compounded
- Wegovy
- Wegovy Oral
- Ozempic
- Rybelsus

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [How To Reconstitute Semaglutide: Simple & Safe](<https://pepflow.app/blog/how-to-reconstitute-semaglutide/>)
- [Semaglutide dosage guide](<https://pepflow.app/peptides/semaglutide/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
